RA0123 manuscript supplemental information the mean response of the certolizumab pegol-IR plus bimekizumab group, and for the coefficient of model covariate, a vague prior distribution was assumed; for the certolizumab pegol-IR plus placebo group, an informative prior distribution was assumed. Patients that did not have available data were included in the analysis as a random variable in the Bayesian framework.
Sensitivity analyses of the primary efficacy endpoint
Sensitivity analyses were conducted to assess the strength of evidence when the informative prior was replaced with a vague prior, thus remove the leveraging of historical data. A sensitivity analysis was conducted by repeating the primary analysis assuming vague priors for all parameters of the model. A second sensitivity analysis was conducted by repeating the primary analysis for all randomised patients in the per protocol set (PPS; patients in the FAS who had no major protocol deviations) to evaluate the effect of important protocol deviations. The third sensitivity analyses repeated the primary analysis assuming vague priors for all parameters of the model for all randomised patients in the PPS to evaluate the effect of the influence of the prior distribution on the PPS. The fourth sensitivity analysis used a mixed model with repeated measures (MMRM) to evaluate the change from Baseline 2 in DAS28(CRP) at Week 20. This used all available change from Week 8 in DAS28(CRP) at all visits up to and including Week 20, incorporated as repeated measures within each subject. Treatment group, visit, and treatment group by visit interaction were included as fixed effects. The Week 8 values in DAS28(CRP) were used as a covariate and an unstructured covariance matrix was utilised.
Bayesian analysis of secondary efficacy endpoints
DAS28(CRP) remission at Week 20 was analysed using a logistic regression model to evaluate treatment response at Week 20. Treatment group, visit, and treatment group by visit interaction were included as fixed effects and the DAS28(CRP) value at Week 8 as a covariate in the model. A Bayesian analysis using a logistic model with vague prior distributions was conducted for DAS28(CRP) remission at Week 20.
Additional efficacy analyses
Additional analyses were performed to determine if the improvement in DAS28(CRP) at Week 20 could be attributed to one of the components. This analytical approach aimed to determine the drivers of remission by removing any potential over-influence of the patient global assessments or the CRP response and by utilising direct calculation of DAS28(CRP) remission and Boolean remission. 
Results

Sensitivity analysis of the primary efficacy variable
The results of the four sensitivity analyses at Week 20 were consistent with and supportive of the primary analysis of the primary efficacy variable. The estimated posterior mean treatment difference in DAS28(CRP) change from Week 8 to Week 20 for the randomised set using a vague prior distribution was 0.38 (95% credible interval [CrI]: -0.16, 0.92) with strong evidence that the true treatment difference was >0 (posterior probability of 91.6%).
The estimated posterior mean treatment difference in DAS28(CRP) change from Week 8 to Week 20 for the PPS using an informative prior distribution was 0.61 (95% CrI: 0.15, 1.08) with very strong evidence that the true treatment difference was >0 (posterior probability of 99.6%). The estimated posterior mean treatment difference in DAS28(CRP) change from Week 8 to Week 20 for the PPS using a vague prior distribution for the certolizumab pegol and placebo model parameter was 0.43 (95% CrI: -0.11, 0.98) with strong evidence that the true treatment difference was >0 (posterior probability of 94.0%). The sensitivity analysis of change from Week 2 at Week 20 in DAS28(CRP) using MMRM showed a larger mean decrease in the certolizumab pegol-IR plus bimekizumab group compared with the certolizumab pegol-IR plus placebo group, mean difference from placebo -0.44 (95% CI: -0.98, 0.10); p=0.110.
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ACR20, ACR50 and ACR70 response
The Bayesian analysis of ACR20 response indicated a posterior probability of 69.0% for a greater improvement in ACR20 in the certolizumab pegol-IRplus bimekizumab group compared with the certolizumab pegol plus placebo group at Week 20; estimated posterior mean treatment difference in ACR20 response was 6.3% (95% Crl -17.7, 30.6).
The posterior probability for improvement in ACR50 and ACR70 in the certolizumab pegol-IR plus bimekizumab group compared with certolizumab pegol-IR plus placebo group at Week 20 by Bayesian analysis was 99.6% and 100% respectively. The estimated posterior mean treatment differences in ACR50 and ACR 70 response was 26.5% (95% CrI 8.0, 43.7) and 13.9% (95% CrI 5.4, 25.6), respectively. However, since the ACR70 model didn't converge, these results should be interpreted with caution.
Safety profile of the certolizumab pegol responders group
In the certolizumab pegol responders group, the incidence of treatment-emergent adverse events (TEAEs) was 67.5% (54/80), with serious TEAEs reported for 8.8% (7/80).
Throughout the course of the study, 11.3% (9/80) of patients discontinued due to TEAEs.
Severe TEAEs were reported for 3.8% (3/80) of patients; two patients experienced severe TEAEs of rheumatoid arthritis and one patient experienced a severe TEAE of pregnancy.
There were no deaths in the certolizumab pegol responders group. Skin and subcutaneous disorders 6 (7.5)
Supplemental
Gastrointestinal disorders 5 (6.3)
Blood and lymphatic system disorders 4 (5.0) *n = number of patients reporting at least one TEAE within the SOC/PT TEAEs during treatment were defined as an adverse event that started or worsened on or after the first dose of certolizumab pegol. TEAEs were coded using MedDRA v 19.0 PT, preferred term; SOC, system organ class; TEAE, treatment emergent adverse event
